WO2003049725A2 - Compositions for the treatment of lupus, other rheumatic diseases and joint diseases - Google Patents

Compositions for the treatment of lupus, other rheumatic diseases and joint diseases Download PDF

Info

Publication number
WO2003049725A2
WO2003049725A2 PCT/US2002/039297 US0239297W WO03049725A2 WO 2003049725 A2 WO2003049725 A2 WO 2003049725A2 US 0239297 W US0239297 W US 0239297W WO 03049725 A2 WO03049725 A2 WO 03049725A2
Authority
WO
WIPO (PCT)
Prior art keywords
flavonoid
quercetin
lupus
flavonoids
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/039297
Other languages
French (fr)
Other versions
WO2003049725A3 (en
Inventor
Randy H. Ziegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2002366645A priority Critical patent/AU2002366645A1/en
Priority to BR0207061-8A priority patent/BR0207061A/en
Priority to EP02804752A priority patent/EP1450835B1/en
Priority to DE60214881T priority patent/DE60214881T2/en
Priority to US10/497,563 priority patent/US20040248821A1/en
Priority to US10/426,460 priority patent/US20040028675A1/en
Publication of WO2003049725A2 publication Critical patent/WO2003049725A2/en
Publication of WO2003049725A3 publication Critical patent/WO2003049725A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention concerns a treatment for rheumatic diseases and for joint diseases.
  • Lupus Erythematosus (“Lupus”) is a chronic inflammatory disease that can affect the skin, joints, blood, and kidneys as well as other parts of the body. Lupus is an "autoimmune" disease in which the immune system makes antibodies directed against parts of the body. Normally antibodies react only with bacteria, viruses and other foreign substances. When “self” antibodies are made, damage can occur either through direct antibody mediated attack on body tissues or indirectly from immune complexes. Immune complexes are the reaction products between portions of the body's tissues and the antibodies. These complexes build up in the skin or in joints or in kidneys and cause many of the symptoms of Lupus. Although many cases of Lupus are mild, the disease may cause serious life-threatening symptoms.
  • Lupus is one of a number of "rheumatic" diseases that generally also include an autoimmune component.
  • Inflammation is generally a process wherein circulation to a region of tissue is increase and blood vessel walls become leaky so that white blood cells can infiltrate the region and attack foreign bodies. If autoantibodies are involved the bodies own tissues are attacked and damaged or destroyed. If the inflammation occurs in the joints, the cushioning and lubricating cartilage of the joints can be damaged. This causes frictional damage to the bones of the joint, which can result in more inflammation and more damage. This is why anti-inflammatory drugs are often used to treat Lupus and other inflammatory joint diseases. It is generally believed that some joint diseases such as osteoarthritis are more of a "wear and tear" disease wherein the cartilage is naturally eroded. However, the end product is still inflammation (which causes further damage) so that anti-inflammatory drugs are also effective.
  • anti-inflammatory drugs are non-steroidal anti-inflammatory drugs such as ibuprofen or ketoprofen which act on the inflammatory processes downstream of the white blood cells. Steroids directly affect the white blood cells by slowing their replication or b speeding their destruction through apoptosis.
  • Other effective drugs are cytotoxic drugs such as Imuran which suppress the immune system (and hence inflammation) by damaging rapidly dividing cells such as immune cells.
  • Non-steroidal anti-inflammatory drugs can cause serious damage to the digestive system and often prolong bleeding times. Steroids can be adductive and have a wide range of serious side effects including diabetes. Cytotoxic drugs can result in oversuppression of the immune system with resulting infections and even cancer. Further, many inflammatory diseases —especially Lupus — may not respond adequately to any of the treatments. Consequently, there remains an extreme need for safe and effective treatments for Lupus and other inflammatory diseases.
  • bioflavonoids particularly flavnols such as Quercetin, supplemented with Bromelain and Vitamin C, (500 mg of each, in doses three times a day) completely reverse the symptoms of Lupus and other inflammatory joint diseases.
  • Luteolin, Myricetin and Rutin are also effective bioflavonoids in the present invention.
  • Experimental data indicate that Luteolin is somewhat more effective than Quercetin. Luteolin, however, is currently difficult to obtain economically in quantity.
  • Flavonoids are ubiquitous secondary products found in most land plants. Flavonoids are oxygen based rather than nitrogen based like traditional pharmaceuticals plant compounds such as alkaloids. As such they are end terminus electron acceptors rather than electron donors. Flavonoids inhibit 5-lipoxygenase in the cytokine release pathways because hydroxyl groups at 4', 3, and 7 positions of the flavonoid molecules accept electrons.
  • Flavonoids modulate the immune response through sequestration of free radicals, which prevents formation of epoxide diols and subsequent attack on the DNA. Further, catalytic ion and signal transducers are sequestered by Flavonoids (See, Structural dependence of flavonoid interactions with Cu2 + ions: implications for their antioxidant properties, Brown JE, Khodr H, Hider RC, Rice-Evans CA, Biochem. J. 1 998 Mar 1 5;330 (pt 3) : 1 1 73-8) .
  • flavonoids inhibit Deiodinase, which is the enzyme that promulgates thyroid functions, lodothyronine deiodinase is oxygen bound and directly impacts basal oxygenation. Flavonoids have the steric binding mimicry of ligands that bind the oxygen transport molecule lodothreonine Deiodinase.
  • the flavonoid component of the present invention controls inflammation through its effects on ion channels and possibly through other biological effects not yet elucidated.
  • White blood cells are deactivated by the changes in ion channels so that inflammatory attacks on the joints are decreased.
  • Down regulation of the immune system results in lowered production of auto- antibodies.
  • Bromelain appears to be able to help in joint repair. It does seem likely that Bromelain is in some way synergistic with the flavonoids because treatment with flavonoids but without Bromelain is clearly less effective than the combination.
  • Many natural foods contain flavonoids; however, few, if any, contain Bromelain combined with effective flavonoids.
  • Quercetin which has been used in the majority of tests of the present invention, is very effective in tests of ion channel function. Luteolin is even more effective than Quercetin in such tests. Limited tests have shown that replacing Quercetin with Luteolin in the inventive formula is somewhat more effective. However, at this time the inventor lacks a ready source of pharmaceutical grade Luteolin to demonstrate whether luteolin is significantly more effective overall. Quercetin and Luteolin differ by a single hydroxyl group (which Luteolin lacks as compared to Quercetin) .
  • Rutin is a glycoside (rutinoside) of Quercetin so that metabolism of Rutin is likely to make Quercetin available. It is likely that other flavonoids with structural similarities to quercetin or luteolin, or glycosides of these flavonoids, will also function in the present invention.
  • One of the first tested subjects was, BZ, who had been bed ridden for nine months and could neither sit up or turn over. She showed the typical Lupus butterfly rash and was diagnosed by a blood test showing a positive ANA (anti-nucleic acid antibody) titer— criteria indicative of Lupus.
  • the subject's mother had previously tested positive for Lupus and has been treated with several medications, including Plaquinel and Cyclosporin.
  • a second subject, KA had also tested positive for Lupus and had been being treated with Plaquinel and Cyclosporin.
  • MK was a 65-year-old woman with seropositive rheumatoid arthritis. She developed side effects from methotrexate treatment at a dose of 22.5 mg weekly. Her methotrexate was discontinued and she was started on the inventive composition. Within one month she showed a dramatic decrease in synovitis.
  • NM was a 37-year-old woman with an inflammatory polyarthritis and positive ANA (antinuclear antibody). She had Sjogrens syndrome with a positive SSA (anti-Ro) antibody. After three months of treatment with the inventive composition, she noticed decreased hair loss, and a lessening of joint pain and swellings. Her serologies also improved. Her initial ANA titer was 1 70 and SSA titer was 584, and occasionally much, much higher. Her most recent serologies show an ANA titer of 67 and SSA of 429.
  • DS was a 57 year old female with SLE/Sjogrens. Her disease manifestations were pulmonary infiltrates and pulmonary effusions. Despite high doses of prednisone, plaquenil, and Imuran she had continued pulmonary symptoms, fevers, joint swellings, and elevated anti-DNA antibody. After one-month treatment with the inventive composition, her Anti-DNA level decreased from 454 to 1 86 (normal less than 30) .
  • LC was a 46 year old female with SLE. Her main manifestations have been joint inflammation and recurrent serositis. She has had recurrent chest pain and palpitations. Her echocardiogram in 1 999 showed valvular changes with trace mitral regurgitation and mild to moderate tricuspid regurgitation. She also had pulmonary hypertension with a RV systolic pressure of 45. LC started the inventive compositions and after four months was tapered off prednisone of 20-mg qd and Plaquinel. Her recent echocardiogram shows improvement-there was no longer any evidence of pulmonary hypertension. At this time more than 50 patients, most with some form of Lupus, but others with various inflammatory joint diseases, have been treated with the inventive composition. Virtually all patients have demonstrated a measurable amelioration of their disease state.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A composition and a method for the amelioration of Lupus, related rheumatic diseases and inflammatory joint diseases. The composition consists of a bioflavonoid combined with Bromelain. Vitamin C may be added to the composition to improve its efficacy. The preferred flavonoid is Luteolin or Quercetin. Myricetin may also be used as may be a glycoside such as Rutin that contains either Luteolin, Quercetin or Myricetin as an aglycone. Other effective flavonoids can be selected by their ability to interact with the Kv1.3 channel of lymphocytes. In preferred method of treatment a mixture of flavonoid, Bromelain and Vitamin C is administered at least daily by an oral route. A mixture of 500 mg Quercetin, 500 mg Bromelain and 500 mg Vitamin C administered three times daily is effective.

Description

COMPOSITIONS FOR THE TREATMENT OF LUPUS
Background of the Invention Area of the Art
The present invention concerns a treatment for rheumatic diseases and for joint diseases.
Description of the Prior Art
Lupus Erythematosus ("Lupus") is a chronic inflammatory disease that can affect the skin, joints, blood, and kidneys as well as other parts of the body. Lupus is an "autoimmune" disease in which the immune system makes antibodies directed against parts of the body. Normally antibodies react only with bacteria, viruses and other foreign substances. When "self" antibodies are made, damage can occur either through direct antibody mediated attack on body tissues or indirectly from immune complexes. Immune complexes are the reaction products between portions of the body's tissues and the antibodies. These complexes build up in the skin or in joints or in kidneys and cause many of the symptoms of Lupus. Although many cases of Lupus are mild, the disease may cause serious life-threatening symptoms.
Lupus is one of a number of "rheumatic" diseases that generally also include an autoimmune component. Usually much of the damage of Lupus and other rheumatic diseases is mediated by inflammatory processes. Inflammation is generally a process wherein circulation to a region of tissue is increase and blood vessel walls become leaky so that white blood cells can infiltrate the region and attack foreign bodies. If autoantibodies are involved the bodies own tissues are attacked and damaged or destroyed. If the inflammation occurs in the joints, the cushioning and lubricating cartilage of the joints can be damaged. This causes frictional damage to the bones of the joint, which can result in more inflammation and more damage. This is why anti-inflammatory drugs are often used to treat Lupus and other inflammatory joint diseases. It is generally believed that some joint diseases such as osteoarthritis are more of a "wear and tear" disease wherein the cartilage is naturally eroded. However, the end product is still inflammation (which causes further damage) so that anti-inflammatory drugs are also effective.
The most commonly used anti-inflammatory drugs are non-steroidal anti-inflammatory drugs such as ibuprofen or ketoprofen which act on the inflammatory processes downstream of the white blood cells. Steroids directly affect the white blood cells by slowing their replication or b speeding their destruction through apoptosis. Other effective drugs are cytotoxic drugs such as Imuran which suppress the immune system (and hence inflammation) by damaging rapidly dividing cells such as immune cells.
As will be appreciated, all of these drug treatments can have serous side effects. Non-steroidal anti-inflammatory drugs can cause serious damage to the digestive system and often prolong bleeding times. Steroids can be adductive and have a wide range of serious side effects including diabetes. Cytotoxic drugs can result in oversuppression of the immune system with resulting infections and even cancer. Further, many inflammatory diseases — especially Lupus — may not respond adequately to any of the treatments. Consequently, there remains an extreme need for safe and effective treatments for Lupus and other inflammatory diseases.
Summary of the Invention
The inventor has found that bioflavonoids, particularly flavnols such as Quercetin, supplemented with Bromelain and Vitamin C, (500 mg of each, in doses three times a day) completely reverse the symptoms of Lupus and other inflammatory joint diseases. Luteolin, Myricetin and Rutin are also effective bioflavonoids in the present invention. Experimental data indicate that Luteolin is somewhat more effective than Quercetin. Luteolin, however, is currently difficult to obtain economically in quantity.
While not wishing to be bound to a single explanation for the working of the present invention, the inventor believes that a significant part of the efficacy is due to the effects of specific bioflavonoids on certain cellular ion channels. In the past it has been shown that abnormal potassium channel expression in certain autoimmune diseases is related to the abnormal immune response. (See "Abnormal K+ channel expression in Autoimmune Diseases..." by Chandy and Cahalan published in 1 990 by the University of California at Irvine and "Autoimmune diseases linked to abnormal K+ channel expression in double-negative CD4~CD8~T cells," Eur J. Immunol, Cahalan MD, Chandy GK, Grissmer S., 1 990, 20: 747- 751 ). It was shown rats with experimental SLE (Systemic Lupus Erythematosus), Diabetes (Type I) and EAE (Experimental Autoimmune Encephalitis) were tested for the Kv1 .3 channel, and it was shown found that all three have the CD4" and CD8"-T-Cells (double negative T-Cells) expression that inflames the various tissues associated with the respective diseases. All of these diseases show a control of lymphocyte proliferation by the Kv1 .3 channel. It has independently been demonstrated that flavonoids, especially Quercetin, are very effective at modulating the conduction by this potassium channel. This suggested to the inventor that flavonoids could be effective in controlling human Lupus.
Detailed Description of the Invention
The following description is provided to enable any person skilled in the art to make and use the invention and sets forth the best modes contemplated by the inventor of carrying out his invention. Various modifications, however, will remain readily apparent to those skilled in the art, since the general principles of the present invention have been defined herein specifically to provide an effective treatment for Lupus and other autoimmune and inflammatory joint diseases
Flavonoids are ubiquitous secondary products found in most land plants. Flavonoids are oxygen based rather than nitrogen based like traditional pharmaceuticals plant compounds such as alkaloids. As such they are end terminus electron acceptors rather than electron donors. Flavonoids inhibit 5-lipoxygenase in the cytokine release pathways because hydroxyl groups at 4', 3, and 7 positions of the flavonoid molecules accept electrons. (See, Effects of FLAVONOIDS on Arachidonic Acid Metabolism, A. F. Welton, L.D. Tobias, The Biochemistry of Cell Activation Related to the Putative Action of FLAVONOIDS, S. G. Laychock, Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological, and Structure-Activity Relationships, pg 231 -242, 1 986 Alan R Liss, Inc.). Flavonoids modulate the immune response through sequestration of free radicals, which prevents formation of epoxide diols and subsequent attack on the DNA. Further, catalytic ion and signal transducers are sequestered by Flavonoids (See, Structural dependence of flavonoid interactions with Cu2+ ions: implications for their antioxidant properties, Brown JE, Khodr H, Hider RC, Rice-Evans CA, Biochem. J. 1 998 Mar 1 5;330 (pt 3) : 1 1 73-8) .
A number of biological effects of flavonoids have been elucidated. For example, flavonoids inhibit Deiodinase, which is the enzyme that promulgates thyroid functions, lodothyronine deiodinase is oxygen bound and directly impacts basal oxygenation. Flavonoids have the steric binding mimicry of ligands that bind the oxygen transport molecule lodothreonine Deiodinase. ("Role of FLAVONOIDS in the Oxygen-free Radical Modulation of Immune Responses", B. Pignol, et. al., Role of Flavonoids in the Oxygen-Free Radical Modulation of the Immune Response, Plant Flavonoids in Biology and Medicine II: Biochemical, Cellular, and Medicinal Properties, pg. 1 73-1 82, 1 988 Alan R. Liss, Inc.; "Structure Activity Relationships of FLAVONOIDS Deiodinase Inhibitors and Enzyme Active Site Model", S. V. Cody, Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological, and Structure-Activity Relationships, 1 986 Alan R. Liss, Inc., pg. 373-382). Flavonoids thus "turn down the thermostat" of homeostasis. ("lodothyronine Deiodinase is Inhibited by Plant FLAVONOIDS", J. Koehrle pg. 324, Structure Activity Relationships of FLAVONOIDS Deiodinase Inhibitors and Enzyme Active Site Model, S. V. Cody, Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological, and Structure-Activity Relationships, 1 986 Alan R. Liss, Inc., pg. 373-382).
It is believed that the effect of flavonoids in the present invention is mediated through the above-discussed effect on ion channels. However, the effect on the thyroid indicates that the flavonoids may be acting on more than one biological system in the present invention. The inventor included Bromelain in the present invention because there is some indication that this enzyme can aid in the regeneration of cartilage in a damaged joint. Generally, Bromelain alone is not effective in ameliorating the joint pain in either osteoarthritis or Lupus caused joint inflammation. It is logical that the compound is not effective in Lupus because continued Lupus-induced inflammation would mask any joint repairing effects of Bromelain. It also seems apparent that osteoarthritis, at least in some cases, is mediated by an inflammatory process. This may explain why Bromelain treatment of that disease has not been very effective.
However, the flavonoid component of the present invention controls inflammation through its effects on ion channels and possibly through other biological effects not yet elucidated. White blood cells are deactivated by the changes in ion channels so that inflammatory attacks on the joints are decreased. Down regulation of the immune system (as mediated by white blood cells) results in lowered production of auto- antibodies. Under these conditions Bromelain appears to be able to help in joint repair. It does seem likely that Bromelain is in some way synergistic with the flavonoids because treatment with flavonoids but without Bromelain is clearly less effective than the combination. Many natural foods contain flavonoids; however, few, if any, contain Bromelain combined with effective flavonoids. Also, it is not known whether the combination of flavonoids in natural products might decrease the overall effectiveness of the "correct" flavonoids. For whatever reasons mere dietary treatments for Lupus and related diseases has not been successful. While the present inventor believes that the addition of vitamin C to the flavonoid/Bromeiain mixture enhances the effect of the mixture, it is apparent that the mixture without vitamin C is also effective. However, because vitamin C is relatively innocuous, it has been used in the vast majority of tests.
Screening tests by experts in ion channel function have indicated that a number of flavonoids, especially certain flavonols have the correct charge structure to regulate the key ion channels. Quercetin, which has been used in the majority of tests of the present invention, is very effective in tests of ion channel function. Luteolin is even more effective than Quercetin in such tests. Limited tests have shown that replacing Quercetin with Luteolin in the inventive formula is somewhat more effective. However, at this time the inventor lacks a ready source of pharmaceutical grade Luteolin to demonstrate whether luteolin is significantly more effective overall. Quercetin and Luteolin differ by a single hydroxyl group (which Luteolin lacks as compared to Quercetin) . A limited number of tests have shown that Myricetin is somewhat effective in the present; this compound varies from Quercetin in the addition of one hydroxyl. In addition, rutin is also moderately effective in the present invention. Rutin is a glycoside (rutinoside) of Quercetin so that metabolism of Rutin is likely to make Quercetin available. It is likely that other flavonoids with structural similarities to quercetin or luteolin, or glycosides of these flavonoids, will also function in the present invention.
The results of treating actual patients with the inventive composition have been extremely dramatic. Besides the cases described herein literally dozens of patients have shown similar results when treated with the Quercetin/Bromelain/Vitamin C mixture.
One of the first tested subjects was, BZ, who had been bed ridden for nine months and could neither sit up or turn over. She showed the typical Lupus butterfly rash and was diagnosed by a blood test showing a positive ANA (anti-nucleic acid antibody) titer— criteria indicative of Lupus. The subject's mother had previously tested positive for Lupus and has been treated with several medications, including Plaquinel and Cyclosporin. A second subject, KA, had also tested positive for Lupus and had been being treated with Plaquinel and Cyclosporin.
Both of these test subjects experienced rapid relief from symptoms of fatigue and depression and pain, elimination of the associated rash and a return to normal life style within one to two months of beginning a regime of one pill (500 mg Quercetin/500 mg Bromelain/500 mg Vitamin C) three times per day at the above dosage. Kidney flares ceased and pain abrogated. Both subjects stated that they felt completely fine with no side effects and maintained a perfect state of health while on the inventive composition.
Both BZ and KA stopped taking the medication after two months, since they reported that they were "completely recovered." As might be expected, symptoms begin to reappear within two weeks. Upon reestablishment of treatment all symptoms again disappeared. This indicates that the inventive product is solely responsible for the amelioration of SLE (Systemic Lupus Erythematosus) . ■14-
Additional patients have also shown similar positive results. MK was a 65-year-old woman with seropositive rheumatoid arthritis. She developed side effects from methotrexate treatment at a dose of 22.5 mg weekly. Her methotrexate was discontinued and she was started on the inventive composition. Within one month she showed a dramatic decrease in synovitis.
NM was a 37-year-old woman with an inflammatory polyarthritis and positive ANA (antinuclear antibody). She had Sjogrens syndrome with a positive SSA (anti-Ro) antibody. After three months of treatment with the inventive composition, she noticed decreased hair loss, and a lessening of joint pain and swellings. Her serologies also improved. Her initial ANA titer was 1 70 and SSA titer was 584, and occasionally much, much higher. Her most recent serologies show an ANA titer of 67 and SSA of 429.
DS was a 57 year old female with SLE/Sjogrens. Her disease manifestations were pulmonary infiltrates and pulmonary effusions. Despite high doses of prednisone, plaquenil, and Imuran she had continued pulmonary symptoms, fevers, joint swellings, and elevated anti-DNA antibody. After one-month treatment with the inventive composition, her Anti-DNA level decreased from 454 to 1 86 (normal less than 30) .
LC was a 46 year old female with SLE. Her main manifestations have been joint inflammation and recurrent serositis. She has had recurrent chest pain and palpitations. Her echocardiogram in 1 999 showed valvular changes with trace mitral regurgitation and mild to moderate tricuspid regurgitation. She also had pulmonary hypertension with a RV systolic pressure of 45. LC started the inventive compositions and after four months was tapered off prednisone of 20-mg qd and Plaquinel. Her recent echocardiogram shows improvement-there was no longer any evidence of pulmonary hypertension. At this time more than 50 patients, most with some form of Lupus, but others with various inflammatory joint diseases, have been treated with the inventive composition. Virtually all patients have demonstrated a measurable amelioration of their disease state.
The following claims are thus to be understood to include what is specifically illustrated and described above, what is conceptually equivalent, what can be obviously substituted and also what essentially incorporates the essential idea of the invention. Those skilled in the art will appreciate that various adaptations and modifications of the just- described preferred embodiment can be configured without departing from the scope of the invention. The illustrated embodiment has been set forth only for the purposes of example and that should not be taken as limiting the invention. Therefore, it is to be understood that, within the scope of the appended claims, the invention may be practiced other than as specifically described herein.

Claims

I claim:
1 . A composition for the treatment of Lupus and
inflammatory joint diseases comprising flavonoid and Bromelain.
2. The composition according to Claim 1 further
comprising Vitamin C.
3. The composition according to Claim 1 , wherein the
flavonoid is selected from the group consisting of Luteolin, Quercetin,
Myricetin and Rutin.
4. The composition according to Claim 1 , wherein the
flavonoid comprises a flavonol.
5. The composition according to Claim 1 , wherein the
flavonoid comprises a glycoside.
6. The composition according to Claim 5, wherein the
glycoside has an aglycone that is a flavonol.
7. The composition according to Claim 6, wherein the
flavonol is selected from the group consisting of Quercetin, Luteolin and
Myricetin.
8. The composition according to Claim 1 , wherein the
flavonoid is selected to interact with lymphocyte Kv1 .3 channels.
9. The composition according to Claim 6, wherein the
flavonol interacts with lymphocyte Kv1 .3 channels.
1 0. The composition according to Claim 1 , wherein the
flavonoid comprises Quercetin.
1 1 . The composition according to Claim 10 further
comprising Vitamin C.
1 2. A method for the treatment of Lupus and inflammatory
joint diseases in a patient comprising the step of repeatedly administering
flavonoid and Bromelain .
13. The method according to Claim 1 2, wherein the step
of administering further comprises administering Vitamin C.
1 4. The method according to Claim 1 2, wherein the step
of administering is oral administration.
1 5. The method according to Claim 14, wherein the step
of administering is repeated at least daily.
1 6. The method according to Claim 1 5, wherein the step
of administering is repeated at least twice daily.
1 7. The method according to Claim 1 2, wherein the
flavonoid is selected from the group consisting of Luteolin, Quercetin,
Myricetin and Rutin.
1 8. The method according to Claim 1 2, wherein the
flavonoid comprises a flavonol.
1 9. The method according to Claim 1 2, wherein the
flavonoid comprises a glycoside.
20. The method according to Claim 1 9, wherein the
glycoside has an aglycone that is a flavonol.
21 . The method according to Claim 20, wherein the
flavonol is selected from the group consisting of Quercetin, Luteolin and
Myricetin.
22. The method according to Claim 1 2, wherein the
flavonoid is selected to interact with lymphocyte Kv1 .3 channels.
23. The method according to Claim 20, wherein the
flavonol interacts with lymphocyte Kv1 .3 channels.
24. The method according to Claim 1 2, wherein the
flavonoid comprises Quercetin.
25. The method according to Claim 24 further comprising
Vitamin C.
PCT/US2002/039297 2001-12-07 2002-12-09 Compositions for the treatment of lupus, other rheumatic diseases and joint diseases Ceased WO2003049725A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2002366645A AU2002366645A1 (en) 2001-12-07 2002-12-09 Compositions for the treatment of lupus, other rheumatic diseases and joint diseases
BR0207061-8A BR0207061A (en) 2001-12-07 2002-12-09 Composition and method for the treatment of lupus and inflammatory joint diseases
EP02804752A EP1450835B1 (en) 2001-12-07 2002-12-09 Compositions for the treatment of lupus
DE60214881T DE60214881T2 (en) 2001-12-07 2002-12-09 PREPARATIONS FOR THE TREATMENT OF LUPUS
US10/497,563 US20040248821A1 (en) 2001-12-07 2002-12-09 Composition for the treatment of lupus
US10/426,460 US20040028675A1 (en) 2001-12-07 2003-04-30 Compositions for the treatment of lupus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33919901P 2001-12-07 2001-12-07
US60/339,199 2001-12-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/426,460 Continuation-In-Part US20040028675A1 (en) 2001-12-07 2003-04-30 Compositions for the treatment of lupus

Publications (2)

Publication Number Publication Date
WO2003049725A2 true WO2003049725A2 (en) 2003-06-19
WO2003049725A3 WO2003049725A3 (en) 2003-10-02

Family

ID=23327940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039297 Ceased WO2003049725A2 (en) 2001-12-07 2002-12-09 Compositions for the treatment of lupus, other rheumatic diseases and joint diseases

Country Status (8)

Country Link
US (1) US20040248821A1 (en)
EP (1) EP1450835B1 (en)
CN (1) CN1606448A (en)
AT (1) ATE339962T1 (en)
AU (1) AU2002366645A1 (en)
BR (1) BR0207061A (en)
DE (1) DE60214881T2 (en)
WO (1) WO2003049725A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10321725A1 (en) * 2003-05-14 2004-12-02 Mucos Pharma Gmbh & Co Enzyme-containing compositions, dietetic foods and pharmaceuticals made therefrom and their use for medical purposes
WO2007084857A3 (en) * 2006-01-13 2007-09-07 Harvard College Methods and compositions for treating cell proliferative disorders

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1327834C (en) * 2004-10-12 2007-07-25 中国药科大学 Pharmaceutical composition for prevention and cure of skin pruritus
WO2009073930A1 (en) * 2007-12-12 2009-06-18 Dacy Tech Pty Ltd Nutraceutical composition and methods of use
US10376550B2 (en) 2007-12-12 2019-08-13 Dacy Tech Pty Ltd. Nutraceutical composition and methods of use
NZ586723A (en) * 2007-12-12 2012-09-28 Dacy Tech Pty Ltd Use of Biota orientalis for treating osteoarthritis
ES2616231T3 (en) 2008-08-21 2017-06-12 Immunogenics Llc Formulation for oral protein administration
WO2010075611A1 (en) * 2009-01-05 2010-07-08 Bio - Enhancements Pty Ltd Composition comprising proanthocyanidin, proteolytic enzyme and aloe vera/agave species substance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19957318A1 (en) * 1999-11-29 2001-06-21 Mucos Pharma Gmbh & Co Influence of TGF-beta by proteolytic enzymes
AU2001277940A1 (en) * 2000-07-20 2002-02-05 Bradford D. Pitman Dietary supplement compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10321725A1 (en) * 2003-05-14 2004-12-02 Mucos Pharma Gmbh & Co Enzyme-containing compositions, dietetic foods and pharmaceuticals made therefrom and their use for medical purposes
WO2007084857A3 (en) * 2006-01-13 2007-09-07 Harvard College Methods and compositions for treating cell proliferative disorders

Also Published As

Publication number Publication date
BR0207061A (en) 2004-02-17
CN1606448A (en) 2005-04-13
EP1450835A2 (en) 2004-09-01
AU2002366645A1 (en) 2003-06-23
EP1450835B1 (en) 2006-09-20
US20040248821A1 (en) 2004-12-09
DE60214881T2 (en) 2007-05-03
ATE339962T1 (en) 2006-10-15
WO2003049725A3 (en) 2003-10-02
DE60214881D1 (en) 2006-11-02
AU2002366645A8 (en) 2003-06-23

Similar Documents

Publication Publication Date Title
Seyam et al. Clinical utility of ozone therapy for musculoskeletal disorders
Thornhill et al. Natural treatment of perennial allergic rhinitis
Pavan et al. Properties and therapeutic application of bromelain: a review
Jiang et al. The impact of micronized purified flavonoid fraction on the treatment of acute haemorrhoidal episodes
KR20100057535A (en) Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
AU2007280625B2 (en) Use of escin
EP1450835B1 (en) Compositions for the treatment of lupus
US20060252727A1 (en) Medicinal compositions and therapeutic methods for treating arthritis and other painful conditions
Shishehbor et al. Quercetin effectively quells peanut-induced anaphylactic reactions in the peanut sensitized rats
Bhoi et al. Mechanistic prospective and pharmacological attributes of quercetin in attenuation of different types of arthritis
PT991424E (en) PHARMACEUTICAL COMPOSITIONS COMPOSING AN ALDOSE REDUCTASE INHIBITOR AND ACE INHIBITOR
Imo et al. Histological and hepatoprotective effect of ethanolic leaf extract of Gongronema latifolium Benth in acetaminophen-induced hepatic toxicity in male albino rats
US20040028675A1 (en) Compositions for the treatment of lupus
Wala Clinical evaluation of anti-Inflammatory properties of combination of bromelain trypsin and rutoside with combination of ibuprofen trypsin and chymotrypsin following third molar extraction–A comparative study
EP4631508A2 (en) Novel association of gastrodia elata and vitamin d
Földi-Börcsök et al. Lymphedema and vitamins
EP4125850B1 (en) Sodium butyrate for use in the prevention or treatment of rhinovirus infection
CN111603465A (en) Application of lovastatin in preparation of medicine for treating new coronary pneumonia
CN100469390C (en) Application of Bromelain in Preparation of Drugs for Raising Individual IL-8 Content
CN111632055A (en) Application of rosuvastatin calcium in preparation of medicine for treating new coronary pneumonia
RU2806345C2 (en) Composition for phleboprotector and a method of its preparation
CN118717780A (en) Application of rhubarb glycoside in the preparation of medicine for preventing and treating rheumatoid arthritis
KR20240049578A (en) How to Treat Migraine and Related Headache Symptoms with Tricaprilin
KR20030007686A (en) Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
Thompson et al. Nocturnal metiamide treatment in the management of healed duodenal ulceration.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10426460

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10497563

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002804752

Country of ref document: EP

Ref document number: 20028243641

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002804752

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWG Wipo information: grant in national office

Ref document number: 2002804752

Country of ref document: EP